Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
P3 Health PartnersPIII +0.10%43 EV-to-EBITDA is -2.48 as of Jul. 28, 2026. GuruFocus rates PIII with a GF Score™ of 43/100 and a GF Value™ of $8.75 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 509 Healthcare Providers & Services companies, P3 Health Partners ranks worse than 196463.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, P3 Health Partners's enterprise value is $344 Mil.
P3 Health Partners's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-139 Mil. Therefore, P3 Health Partners's EV-to-EBITDA for today is -2.48.
The historical rank and industry rank for P3 Health Partners's EV-to-EBITDA or its related term are showing as below:
PIII'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.4 Med: -1.94 Max: -0.43
Current: -2.48
During the past 8 years, the highest EV-to-EBITDA of P3 Health Partners was -0.43. The lowest was -26.40. And the median was -1.94.
PIII's EV-to-EBITDA is ranked worse than 100% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.03
vs PIII: -2.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
P3 Health Partners (NAS:PIII) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
P3 Health Partners's PE Ratio (TTM) for today is calculated as:
P3 Health Partners's share price for today is $10.52.
P3 Health Partners's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for P3 Health Partners's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, P3 Health Partners's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
P3 Health Partners EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, P3 Health Partners's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where P3 Health Partners's EV-to-EBITDA falls into.
P3 Health Partners's current Enterprise Value is $344 Mil.
P3 Health Partners's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-139 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
P3 Health Partners (PIII) has a EV-to-EBITDA of -2.48 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on P3 Health Partners. According to the industry distribution chart, P3 Health Partners ranks #999999 out of 509 companies in the Healthcare Providers & Services industry.
Is P3 Health Partners' EV-to-EBITDA too high?
P3 Health Partners' current EV-to-EBITDA is -2.48. Based on the distribution chart, P3 Health Partners ranks #999999 out of 509 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, P3 Health Partners has a GF Score™ of 43/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does P3 Health Partners' EV-to-EBITDA compare to CCEL and EHSI?
According to the Healthcare Providers & Services industry distribution chart, P3 Health Partners ranks #999999 out of 509 companies for EV-to-EBITDA. This places P3 Health Partners in the lower half of its industry. The industry median EV-to-EBITDA is 11.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.03, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on P3 Health Partners. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. P3 Health Partners's current EV-to-EBITDA is -2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is P3 Health Partners stock overvalued right now?
Based on GuruFocus' analysis, P3 Health Partners (PIII) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.75, compared to a current price of $10.52 — trading 20.2% above its estimated fair value. The current EV-to-EBITDA is -2.48. P3 Health Partners' overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For P3 Health Partners (PIII), the current EV-to-EBITDA is -2.48 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is P3 Health Partners (PIII) Overvalued in 2026?
Based on GuruFocus' analysis, P3 Health Partners stock appears to be overvalued.
The current stock price of $10.52 is trading 20.2% above its estimated GF Value™ of $8.75.
GuruFocus considers P3 Health Partners to be Modestly Overvalued.
Key valuation signals for PIII:
EV-to-EBITDA: -2.48
GF Value™: $8.75 vs. price of $10.52 (20.2% above fair value)
No single metric tells the full story. See the PIII stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
43GF Score
Get the complete analysis for PIII
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PIII has been successfully added to your 
